New strategies to improve clinical outcomes for diabetic kidney disease

被引:0
作者
Thomas Forst
Chantal Mathieu
Francesco Giorgino
David C. Wheeler
Nikolaos Papanas
Roland E. Schmieder
Atef Halabi
Oliver Schnell
Marina Streckbein
Katherine R. Tuttle
机构
[1] Mannheim GmbH,Clinical Research Services
[2] UZ Gasthuisberg,Department of Endocrinology
[3] Katholieke Universiteit,Department of Emergency and Organ Transplantation Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases
[4] University of Bari Aldo Moro,Department of Renal Medicine
[5] University College London,Diabetes Centre, Second Department of Internal Medicine
[6] Democritus University of Thrace,Department of Nephrology and Hypertension
[7] University Hospital Erlangen,Division of Nephrology, Institute of Translational Health Sciences
[8] Clinical Research Services,undefined
[9] Forschergruppe Diabetes e.V.,undefined
[10] University of Washington,undefined
来源
BMC Medicine | / 20卷
关键词
Type 2 diabetes; Diabetic kidney disease; Kidney protective agents;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 301 条
[1]  
Xu G(2018)Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study BMJ. 362 k1497-81
[2]  
Liu B(2016)Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease Nat Rev Nephrol 12 73-56
[3]  
Sun Y(2016)Diabetic kidney disease: world wide difference of prevalence and risk factors J Nephropharmacol 5 49-263
[4]  
Du Y(2019)Diabetic kidney diseases revisited: a new perspective for a new era Mol Metab 30 250-356
[5]  
Snetselaar LG(2021)Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: estimates from Global Burden of Disease 2017 J Diabetes Investig 3 346-644
[6]  
Hu FB(2020)GLP-1 receptor agonists and diabetic kidney disease: a call of attention to nephrologists J Clin Med 9 947-191
[7]  
Thomas MC(2018)Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes N Engl J Med 379 633-2045
[8]  
Cooper ME(2018)Inflammatory mechanisms as new biomarkers and therapeutic targets for diabetic kidney disease Adv Chronic Kidney Dis 25 181-Ff31
[9]  
Zimmet P(2017)Diabetic kidney disease: challenges, progress, and possibilities Clin J Am Soc Nephrol 12 2032-3952
[10]  
Gheith O(2017)Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets Am J Physiol Ren Physiol 312 F716-1446